DSIP: Dosing Protocols
Dosing guidelines, reconstitution, and administration information
๐TL;DR
- โข3 dosing protocols documented
- โขReconstitution instructions included
- โขStorage: Store lyophilized powder at -20C protected from light and moisture. Reconstituted solutions should be used promptly or stored at 2-8C for no more than 24 hours. DSIP is susceptible to degradation in solution.
Protocol Quick-Reference
Sleep quality improvement and insomnia management
Dosing
Amount
100-300 mcg subcutaneous; 25 nmol/kg IV (~1.5 mg for 70 kg person)
Frequency
Once daily before bed; or every 2-3 days
Duration
10-30 days; effects may persist 3-7 months after a 10-day course
Administration
Route
SCSchedule
Once daily before bed; or every 2-3 days
Timing
Evening, 30-60 minutes before desired sleep onset; some sources suggest 2-3 hours before bed
โ Rotate injection sites
Cycle
Duration
10-30 days; effects may persist 3-7 months after a 10-day course
Repeatable
Yes
Course-based protocol with rest periods
Preparation & Storage
Diluent: Bacteriostatic water
Use within: 24 hours
Storage: Store lyophilized powder at -20C protected from light and moisture. Reconstituted solutions should be used promptly or stored at 2-8C for no more than 24 hours. DSIP is susceptible to degradation in solution.
โ๏ธ Suggested Bloodwork (5 tests)
CBC
When: Baseline
Why: General health baseline
CMP
When: Baseline
Why: Liver and kidney function
Cortisol (morning)
When: Baseline
Why: DSIP may modulate cortisol and stress hormones
Cortisol
When: 2 weeks
Why: DSIP has been reported to normalize cortisol levels
Morning cortisol
When: Ongoing
Why: DSIP normalizes stress hormones; significant changes warrant monitoring
โ ๏ธ DSIP normalizes stress hormones; significant changes warrant monitoring
๐ก Key Considerations
- โA 10-day course of daily injections showed the best results in clinical studies
- โContraindication: Limited safety data; avoid in pregnancy; use caution with concurrent sedative medications
Unlock dosing protocols
Free access to research-backed dosing information for all peptides.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
| Purpose | Dose | Frequency | Duration | Notes |
|---|---|---|---|---|
| Sleep research (human clinical studies) | 25 nmol/kg body weight | Single injection before sleep | Variable; studies used 1-10 administrations | Intravenous administration used in most clinical studies |
| Repeated administration protocol | 25 nmol/kg body weight | Once daily before sleep | 10 consecutive days | Open-label studies showed sustained benefit after treatment cessation |
| Preclinical sleep studies | 0.1-30 nmol ICV | Single administration | Acute study design | Intracerebroventricular route in animal models |
Unlock full dosage protocols
Free access to complete dosing tables and protocol details.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
๐Reconstitution Instructions
Reconstitute lyophilized DSIP in sterile bacteriostatic water or physiological saline. Prepare fresh solutions for each use due to limited stability in solution. Handle with standard peptide precautions.
Recommended Injection Sites
- โIntravenous (used in most human studies)
- โSubcutaneous (alternative route)
- โIntranasal (explored in some research)
๐งStorage Requirements
Store lyophilized powder at -20C protected from light and moisture. Reconstituted solutions should be used promptly or stored at 2-8C for no more than 24 hours. DSIP is susceptible to degradation in solution.
Community Dosing Protocols
Compare these clinical doses with what 80+ community members report using.
Based on 80+ community reports
View community protocolsResearch Tools
Before You Begin
Review safety warnings and contraindications before starting any protocol.
Research Dosing Disclaimer#
DSIP is not approved for human therapeutic use by any regulatory agency. No official dosing guidelines exist. The dosing information below is derived exclusively from published clinical research studies and is provided for educational purposes only.
Dosing from Human Clinical Studies#
Intravenous Administration#
The most commonly used dose in human clinical studies was 25 nmol/kg body weight administered intravenously. This dose was used in both single-dose and repeated-dose protocols. For a 70 kg individual, this corresponds to approximately 1,750 nmol (about 1.5 mg) per dose.
In the double-blind study by Schneider-Helmert and Schoenenberger, single intravenous injections of 25 nmol/kg before bedtime produced measurable improvements in sleep parameters compared to placebo. The effects of single administration were modest, leading to the development of repeated-dose protocols.
Repeated Dosing Protocols#
The most promising clinical results were obtained with repeated administration protocols, typically consisting of 10 daily intravenous injections at 25 nmol/kg. In an open study of patients with severe insomnia, this protocol normalized sleep in 6 of 7 patients, with effects persisting for 3 to 7 months after the treatment period ended.
The observation that DSIP effects build up with repeated administration and persist after cessation suggests a mechanism of action involving normalization of sleep-regulatory systems rather than direct sedation. This pattern contrasts with conventional sleep medications, which typically produce acute effects that dissipate immediately upon discontinuation.
Dose-Response Relationships#
Limited dose-response data exist for DSIP in humans. Most clinical studies used a standard dose of 25 nmol/kg based on the original clinical pharmacology work. Whether lower or higher doses would produce different therapeutic profiles has not been systematically investigated.
Preclinical Dosing Information#
Central Administration#
In animal studies, DSIP is typically administered intracerebroventricularly (ICV) at doses of 0.1 to 30 nmol. The ICV route ensures direct CNS delivery and avoids the rapid peripheral degradation that occurs with systemic administration. Sleep-promoting effects are generally observed within 30 minutes of ICV administration and can persist for several hours.
Peripheral Administration#
Systemic (intravenous or intraperitoneal) administration of DSIP in animals requires substantially higher doses to achieve comparable effects to central administration, reflecting the peptide's rapid plasma degradation and limited blood-brain barrier penetration.
Administration Routes#
| Route | Context | Typical Dose | Onset | Notes |
|---|---|---|---|---|
| Intravenous | Human studies | 25 nmol/kg | 30-60 min | Most clinical evidence |
| Subcutaneous | Alternative route | Dose not well established | Variable | Limited clinical data |
| Intranasal | Exploratory | Under investigation | Variable | May bypass BBB to some degree |
| ICV | Animal research | 0.1-30 nmol | 15-30 min | Direct CNS delivery |
Reconstitution and Preparation#
DSIP is supplied as a lyophilized powder. For reconstitution:
- Allow the vial to reach room temperature
- Add sterile bacteriostatic water or physiological saline
- Gently swirl to dissolve; do not shake vigorously
- Use the reconstituted solution promptly, as DSIP has limited stability in solution
- If storage is necessary, refrigerate at 2-8 degrees C and use within 24 hours
The short stability of DSIP in solution is due to its susceptibility to enzymatic degradation and potential oxidation of the tryptophan residue. For research applications requiring longer storage, solutions should be aliquoted and frozen at -80 degrees C.
Storage Guidelines#
- Lyophilized powder: Store at -20 degrees C, protected from light and moisture. Stable for at least 12 months under proper conditions.
- Reconstituted solution: Use immediately or refrigerate at 2-8 degrees C for no more than 24 hours.
- Frozen aliquots: -80 degrees C; avoid repeated freeze-thaw cycles.
- Protect from light: The tryptophan residue is susceptible to photooxidation.
Timing Considerations#
In clinical studies, DSIP was administered approximately 30 to 60 minutes before the desired sleep onset. The sleep-promoting effects typically manifested within 30 to 60 minutes of intravenous administration, aligning with the time required for the peptide to reach and act upon central sleep-regulatory circuits.
Related Reading#
Subscribe to see vendor options
Free access to verified vendor scores, pricing, and suppliers.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
Protocol updates
Get notified when we update dosing protocols or publish related comparisons.
Frequently Asked Questions About DSIP
Explore Further
Medical Disclaimer
This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.